TipRanks
55% OFF
PC:CAM4A

cAMPfield

cAMPfield is a biopharmaceutical company developing prifemilast, a potentially best-in-class oral PDE4 inhibitor for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company in-licensed prifemilast from Newsoara Biopharma and was founded by Mountainfield Venture Partners alongside industry executives who played key roles in the development and commercialization of major biologics.

Leadership & Board

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$180M
Total Funding Rounds
1
Latest Funding Amount
$180M
Latest Funding Round
Series A
Post-Money Valuation
―

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Jun 18, 2026Series A$180.00M―

Investors

Investor NameFunding Round
Frazier Life SciencesSeries A
Deep Track CapitalSeries A
ForbionSeries A
AbingworthSeries A
VenrockSeries A
Longitude CapitalSeries A
Novo HoldingsSeries A
RA CapitalSeries A

Similar Companies

A snapshot of private companies similar to cAMPfield, helping you discover and navigate related company profiles.

Related News and Analysis